Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06 Diciembre 2024 - 6:41AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
December, 2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨
No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date: December 6, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: K Randhir Singh |
|
|
Title: Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
December 6, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
| Sub: | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 |
This is to inform that our step-down wholly owned
subsidiary Dr. Reddy’s Laboratories LLC, Ukraine has received an order from State Tax Service of Ukraine. The details as required
under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
Name of the authority |
State Tax Service of Ukraine |
Nature and details of the action(s) taken, initiated or order(s) passed |
Violation of Part 3 of Article 13 of Law No. 2473-VIII dated June 21, 2018 "On Currency and Currency Operations", for delay in receipt of goods by 8 days as stipulated by the said legislation, for which advance payment was made to non-resident entities. Accordingly, a penalty of EUR 280 (~INR 24 K) was levied by the State Tax Service of Ukraine. |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
Date of receipt of order: October 29, 2024.
The delay in disclosure is due to the delay in
receipt of information from the subsidiary Dr. Reddy’s Laboratories LLC, Ukraine. |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
Violation of Part 3 of Article 13 of Law No. 2473-VIII dated June 21, 2018 "On Currency and Currency Operations", for delay in receipt of goods by 8 days as stipulated by the said legislation, for which advance payment was made to non-resident entities. |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
The above order levies a penalty of EUR 280 (~INR 24 K). Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company. |
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Dr Reddys Laboratories (NYSE:RDY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024